RenovoRx's TAMP™ Therapy Shows Promise for Targeting Pancreatic Cancer Treatment

RenovoRx Advances Targeted Therapy for Pancreatic Cancer

RenovoRx, Inc., a life sciences company specializing in targeted oncology therapies, presents significant advancements in its Trans-Arterial Micro-Perfusion (TAMP™) therapy platform at the ASCO Gastrointestinal Cancers Symposium 2025. The recent findings, revealed by Dr. Paula Novelli from the University of Pittsburgh Medical Center, focus on a pharmacokinetic (PK) sub-study from the ongoing Phase III TIGeR-PaC clinical trial. This research specifically evaluates the efficacy of intra-arterial gemcitabine (IAG) delivered through RenovoCath, a device designed to enhance localized drug delivery, compared to the traditional intravenous gemcitabine treatment.

The results from the trial indicate that the IAG method substantially reduces systemic levels of gemcitabine while amplifying the drug's potency at the tumor site. This targeted approach can potentially decrease the systemic side effects commonly associated with chemotherapy, making it an attractive option for patients battling locally advanced pancreatic cancer (LAPC). Dr. Novelli underscores the critical nature of these findings, noting that pancreatic cancer remains one of the most challenging cancers to treat. The data not only highlights the innovative capabilities of TAMP technology but also its potential to significantly improve the quality of life for patients undergoing chemotherapy.

As the TIGeR-PaC trial continues, it represents a pivotal step towards establishing a more efficient and localized treatment modality for LAPC. RenovoRx’s commitment to pioneering cancer therapies through innovative delivery systems is evident in this promising research. The TAMP technology aims to enhance therapeutic efficacy while mitigating the adverse effects that plague conventional chemotherapy methods, positioning RenovoRx as a leader in the fight against pancreatic cancer.

In addition to the promising PK data, RenovoRx continues to solidify its role within the oncology landscape. The company’s FDA-cleared delivery platform, RenovoCath, not only exemplifies its innovative spirit but also aligns with growing industry trends that prioritize precision medicine in cancer treatment. The ongoing studies and data presentations at prestigious conferences like ASCO GI highlight RenovoRx’s dedication to improving patient outcomes through advanced therapeutic strategies.